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We agree with the concerns raised regarding the safety 
of amphetamines such as methylphenidate/dexmethylphe-
nidate1. In fact, we generally support the use of non-phar-
macological interventions, such as cognitive behavioral 
therapy or energy conservation and activity management, 
in all patients after the diagnosis of fatigue is made by one 
of the multiple tools available such as FACIT-F, Visual An-
alogue Scale, Chalder scale, Brief Fatigue Inventory2, and 
others. If fatigue does not improve or if it is severe, phar-
macological therapy should then be judiciously considered.
While the abuse potential of methylphenidate is an 
understandable concern, orally administered methylphe-
nidate at doses prescribed for a therapeutic effect has few 
reinforcing properties3. In fact, psychostimulant abuse 
among patients with cancer-related fatigue has not been 
reported. Finally, a recent systematic review and meta-
nalysis evaluating psychostimulants for the management 
of cancer-related fatigue included 426 patients and found 
that there was no difference in the frequency of adverse 
events of methylphenidates. Placebo with a combined 
odds ratio of 1.24 (95% CI 0.42, 3.62)4. 
We agree that modafinil certainly may be considered 
an option for treatment-associated cancer-related fatigue 
(chemotherapy or radiotherapy), and recent evidence rec-
ommends its use in cases of severe fatigue and in patients 
with advanced disease5-7. However, evidence supporting 
the use of modafinil in mild or moderate fatigue does not 
exist. Although the authors state otherwise, they refer to a 
review article that makes no specific assertion regarding 
the use of modafinil according to fatigue severity, and pri-
marily references the study by Jean-Pierre et al. that found 
modafinil to be effective only in severe fatigue8.
Regarding the use of erythropoietin stimulating agents 
(ESA), our review described the recent evidence and rec-
ommendations on this topic thoroughly, including the 
concerns related to prothrombotic states and the recently 
raised possibility of ESAs stimulating tumor growth9-12.
Guarana (Paullinia cupana) is a plant native to the 
central Amazon, known for its stimulant and aphro-
disiac properties, and popular for its use in energy 
drinks13,14. In a randomized, double-blinded, crossover 
clinical trial published by our group, guarana demon-
strated favorable effects on fatigue during chemotherapy15. 
The stimulant properties of guarana are generally taken 
to reflect the presence of caffeine, which comprises only 
2.5%–5% of the extract’s dry weight, although other purine 
alkaloids (theophylline and theobromine) are present in 
smaller quantities. The doses we used in this study (50 mg 
PO BID) would have negligible amounts of caffeine. Fur-
thermore, no significant increase in cardiovascular events 
has been demonstrated in any study to date, but larger tri-
als are needed to evaluate this promising therapeutic op-
tion for cancer-related fatigue.
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